The current combination of drugs can be used together without serious consequences for your health. Always consult with a medical specialist before using this combination.
Truvada belongs to the antiretroviral combination drug class. It contains two active ingredients: tenofovir-DF and emtricitabine (EM). It’s a highly effective medicine recommended by various anti-HIV guidelines as well as healthcare providers. It’s used to treat HIV infection and as pre-exposure prophylaxis (PrEP) and PEP (nonoccupational as well as occupational exposure) [1].
Tivicay belongs to the integrase strand transfer inhibitor (INSTI) drug class with dolutegravir as an active substance. It’s a highly potent antiretroviral medicine used in combination with other ARV meds to treat HIV infection [2].
Based on metabolism and elimination from clinical tests, there is no significant interaction between the two meds when coadministered. There is no dosage adjustment needed. This does not mean that interactions cannot exist. A combination of these drugs has not been studied, and it’s important to consult with a medical specialist before administering them.
Clinical pharmacokinetic interaction showed that coadministration of TDF and dolutegravir lowered dolutegravir Cmax by 3% and Ctrough by 8% and increased AUC by 1%. Tenofovir Cmax, AUC, and Ctrough values increased by 9%, 12%, and 19% respectively [3].